Brief Reports
Copyright ©The Author(s) 2001. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 15, 2001; 7(6): 872-875
Published online Dec 15, 2001. doi: 10.3748/wjg.v7.i6.872
Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats
Li Yao, Zhen-Min Yao, Tao Yu
Li Yao, Pharmacology Department of Zhejiang College of Traditional Chinese Medicine (TCM), Hangzhou 310053, Zhejiang Province, China
Zhen-Min Yao, Tao Yu, Basic Medicine Department of Zhejiang College of TCM, Hangzhou 310053, Zhejiang Province, China
Author contributions: All authors contributed equally to the work.
Supported by the Natural Science Foundation of Zhejiang Province, No.398402.
Correspondence to: Li Yao, Pharmacology Department of Zhejiang College of TCM, Qingnian Road, Binjiang township, Hangzhou 310053, Zhejiang Province, China. ylyj@mail.hz.zj.cn
Received: May 15, 2001
Revised: June 9, 2001
Accepted: June 15, 2001
Published online: December 15, 2001
Abstract

AIM: To study the anti-hepatofibrosis mechanism of Bie Jia Jian oral liquid (BOL).

METHODS: The model was induced by subcutaneous injection of CCl4. BOL was administered and the change of serum hyaluronic acid (HA) and laminin (LN) was observed and the degeneration of liver cells and the degree of fibre hyperplasia analyzed. Changes of ultra micro-structure in liver cells were observed in some samples.

RESULTS: HA was reduced in both the groups with low and high dosage of BOL, which showed a remarkable difference as compared with that of the model group (low dosage group: 376.15 μg/L ± 35.48 μg/L vs 806.07 μg/L ± 98.49 μg/L, P < 0.05; high dosage group: 340.14 μg/L ± 30.18 μg/L vs 806.07 μg/L ± 98.49 μg/L, P < 0.05). The LN content of low and high dosage group of BOL was lower than that of model group (low dosage group: 71.99 μg/L ± 8.15 μg/L vs 133.94 μg/L ± 14.45 μg/L, P < 0.01; high dosage group: 71.68 μg/L ± 11.62 μg/L vs 133.94 μg/L ± 14.45 μg/L, P < 0.01) and colchicine group (low dosage group: 71.99 μg/L ± 8.15 μg/L vs 118.28 μg/L ± 16.13 μg/L, P < 0.05; high dosage group: 71.68 μg/L ± 11.62 μg/L vs 118.28 μg/L ± 16.13 μg/L, P < 0.05). Examined by Ridit, BOL could reduce the degeneration and necrosis of liver cells (χ² = 11. 99 P < 0.05), the degree of fibre hyperplasia (χ² = 13.24 P < 0.05) and the pathological change of ultra micro-structure as well.

CONCLUSION: The BOL has certain therapeutic effect on the experiment hepatofibrosis. Its mechanisms might include: protecting the function of liver cells, inhibiting excessive synthesis and secretion of extracelluar matrix from hepatic stellate cells, relieving the capillarization of hepatic sinusoid, improving liver micro-circulation, and regulating immune function.

Keywords: BIEJIA JIAN PILL/administration dosage; BIEJIA JIAN PILL/pharmacology; peroral liquids; liver cirrhosis, experiment al/TCD therapy; laminin/analysis; hyaluronic acid/analysis